Clinical Trial Update: Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule [Phase 3]

View source ↗

Summary

Phase 3 trial updating immunogenicity and safety of FSME-IMMUN 0.5 mL in adults previously vaccinated under a rapid schedule is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Encephalitis Tick-borne

Drugs mentioned

• FSME-IMMUN (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-Borne | Phase 3 | Status: COMPLETED